New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis.

Details

Ressource 1Download: New Autoantibody Specificities in Systemic Sclerosis and Very.pdf (1644.26 [Ko])
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_A944932E1A0F
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
New Autoantibody Specificities in Systemic Sclerosis and Very Early Systemic Sclerosis.
Journal
Antibodies
Author(s)
Lande R., Palazzo R., Mennella A., Pietraforte I., Cadar M., Stefanantoni K., Conrad C., Riccieri V., Frasca L.
ISSN
2073-4468 (Electronic)
ISSN-L
2073-4468
Publication state
Published
Issued date
28/03/2021
Peer-reviewed
Oui
Volume
10
Number
2
Pages
12
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Chemokine (C-X-C motif) ligand 4 (CXCL4) is a biomarker of unfavorable prognosis in Systemic Sclerosis (SSc), a potentially severe autoimmune condition, characterized by vasculitis, fibrosis and interferon (IFN)-I-signature. We recently reported that autoantibodies to CXCL4 circulate in SSc patients and correlate with IFN-α. Here, we used shorter versions of CXCL4 and CXCL4-L1, the CXCL4 non-allelic variant, to search for autoantibodies exclusively reacting to one or the other CXCL4 form. Moreover, to address whether anti-CXCL4/CXCL4-L1 antibodies were present before SSc onset and predicted SSc-progression, we longitudinally studied two VEDOSS (Very Early Diagnosis of Systemic Sclerosis) patient cohorts, separating SSc-progressors from SSc-non-progressors. We found that anti-CXCL4-specific autoantibodies were present in both SSc and VEDOSS patients (both SSc-progressors and SSc-non-progressors). Anti-CXCL4-L1-specific autoantibodies were especially detected in long-standing SSc (lsSSc). Anti-CXCL4/CXCL4-L1 antibodies correlated with IFN-α and with specific SSc-skin features but only in lsSSc and not in early SSc (eaSSc) or VEDOSS. Thus, a broader antibody response, with reactivity spreading to CXCL4-L1, is characteristic of lsSSc. The early anti-CXCL4 autoantibody response seems qualitatively different from, and likely less pathogenic than, that observed in advanced SSc. Lastly, we confirm that anti-CXCL4 autoantibodies are SSc-biomarkers and uncover that also CXCL4-L1 becomes an autoantigen in lsSSc.
Keywords
CXCL4-L1, IFN-I signature, Systemic Sclerosis, Very Early Diagnosis of Systemic Sclerosis (VEDOSS), autoantibodies, autoimmune diseases, biomarkers, chemokine (C-X-C motif) ligand 4 (CXCL4)
Pubmed
Web of science
Open Access
Yes
Create date
13/04/2021 14:57
Last modification date
24/02/2022 7:11
Usage data